Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, lower back pain and sore feet, dizziness and blurred vision, thirst, dry tongue and sore throat, and heel pain, as well as rheumatic pain, joint pain, generalized pain, wind-cold-dampness arthralgia, gout, neuralgia, be… Read more
Tien Liang BioTech Co., Ltd. (4127) - Net Assets
Latest net assets as of September 2025: NT$478.29 Million TWD
Based on the latest financial reports, Tien Liang BioTech Co., Ltd. (4127) has net assets worth NT$478.29 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.22 Billion) and total liabilities (NT$745.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$478.29 Million |
| % of Total Assets | 39.09% |
| Annual Growth Rate | 6.81% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.15 |
Tien Liang BioTech Co., Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how Tien Liang BioTech Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tien Liang BioTech Co., Ltd. (2020–2024)
The table below shows the annual net assets of Tien Liang BioTech Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$477.92 Million | -3.05% |
| 2023-12-31 | NT$492.98 Million | +3.76% |
| 2022-12-31 | NT$475.12 Million | +14.75% |
| 2021-12-31 | NT$414.05 Million | +12.74% |
| 2020-12-31 | NT$367.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tien Liang BioTech Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11973600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$29.39 Million | 6.15% |
| Common Stock | NT$457.60 Million | 95.75% |
| Total Equity | NT$477.92 Million | 100.00% |
Tien Liang BioTech Co., Ltd. Competitors by Market Cap
The table below lists competitors of Tien Liang BioTech Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Nordic Metals Corp
OTCQB:FNMCF
|
$22.33 Million |
|
Y-S Electronic Co Ltd
TWO:6418
|
$22.34 Million |
|
Great Elm Group Inc
NASDAQ:GEG
|
$22.34 Million |
|
YeaRimDang Publishing Co. Ltd
KQ:036000
|
$22.34 Million |
|
Arogo Capital Acquisition Corp
NASDAQ:AOGO
|
$22.32 Million |
|
First Bancshares Inc. (Bellevue OH)
PINK:FIBH
|
$22.31 Million |
|
Groupe CRIT SA
PA:CEN
|
$22.30 Million |
|
Medipharm Labs Corp
OTCQX:MEDIF
|
$22.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tien Liang BioTech Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 492,983,000 to 477,924,000, a change of -15,059,000 (-3.1%).
- Net income of 11,696,000 contributed positively to equity growth.
- Dividend payments of 22,880,000 reduced retained earnings.
- Other comprehensive income decreased equity by 1,753,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$11.70 Million | +2.45% |
| Dividends Paid | NT$22.88 Million | -4.79% |
| Other Comprehensive Income | NT$-1.75 Million | -0.37% |
| Other Changes | NT$-2.12 Million | -0.44% |
| Total Change | NT$- | -3.05% |
Book Value vs Market Value Analysis
This analysis compares Tien Liang BioTech Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.42x to 3.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$8.03 | NT$35.45 | x |
| 2021-12-31 | NT$9.05 | NT$35.45 | x |
| 2022-12-31 | NT$10.38 | NT$35.45 | x |
| 2023-12-31 | NT$10.77 | NT$35.45 | x |
| 2024-12-31 | NT$10.22 | NT$35.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tien Liang BioTech Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.04%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.86x
- Recent ROE (2.45%) is below the historical average (3.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -14.06% | -11.98% | 0.69x | 1.70x | NT$-88.36 Million |
| 2021 | 11.26% | 8.16% | 0.87x | 1.58x | NT$5.20 Million |
| 2022 | 12.52% | 11.25% | 0.78x | 1.42x | NT$11.97 Million |
| 2023 | 3.60% | 3.85% | 0.70x | 1.33x | NT$-31.57 Million |
| 2024 | 2.45% | 3.04% | 0.43x | 1.86x | NT$-36.10 Million |
Industry Comparison
This section compares Tien Liang BioTech Co., Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tien Liang BioTech Co., Ltd. (4127) | NT$478.29 Million | -14.06% | 1.56x | $22.32 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |